Clinical trial
Multi-center, Two-arm Non-comparative, Observational, 96-week Phase IV Study to Evaluate Treatment Adherence When Using RebiSmart™ for Self-injection of Rebif® in Multi-dose Cartridges in Subjects With Relapsing Multiple Sclerosis (RMS)
NCT01128075 is registered in ClinicalTrials.gov with Merck KGaA, Darmstadt, Germany as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- Multi-center, Two-arm Non-comparative, Observational, 96-week Phase IV Study to Evaluate Treatment Adherence When Using RebiSmart™ for Self-injection of Rebif® in Multi-dose Cartridges in Subjects With Relapsing Multiple Sclerosis (RMS)
- Lead sponsor
- Merck KGaA, Darmstadt, Germany
- Phase
- Observational
- Overall status
- Completed
- Start date
- August 31, 2009
- Completion date
- April 30, 2014
- Enrollment
- 198 (actual)
- Sites
- 1
Conditions
As the registry lists them; a condition with its own page is linked.